Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Incyte Corporation | Povorcitinib (INCB54707) | Prurigo Nodularis | Phase 3 | Trial Planned | oral | #N/A |
| Incyte Corporation | Baricitinib - (BRAVE-AA-PEDS) | Severe alopecia areata (AA) | Phase 3 | Data Released | Oral | Immunology |
| Incyte Corporation | Ruxolitinib cream 1.5% - (TRuE-PN1) | Prurigo nodularis (PN) | Phase 3 | Data Released | Topical | #N/A |
| Incyte Corporation | Povorcitinib (INCB54707) | Asthma | Phase 2 | Ongoing | oral | Respiratory |
| Incyte Corporation | INCAGN2385 | Recurrent And/Or Metastatic (R/M) PD-L1+ HNSCC | Phase 2 | Ongoing | Intravenous | Oncology |
| Incyte Corporation | ZYNYZ (retifanlimab-dlwr) - (POD1UM-304) | Non-small cell lung cancer (NSCLC) | PDUFA | Data Released | Intravenous | Oncology |
| Incyte Corporation | Pelareorep and retifanlimab (INCMGA00012) - (IRENE) | Triple-negative breast cancer | Phase 2 | Trial Completed | Intravenous | Oncology |
| Incyte Corporation | MRGPRX2 (INCB000262) | Spontaneous urticaria (CSU) | Phase 2 | Clinical Pause | Intravenous | Immunology |
